Andrew Reiter is Co-Founder and COO at 10x Science, an AI-native platform built to accelerate biopharmaceutical drug development through next-generation protein characterization.

Andrew earned his B.S. in Biology from UNC-Chapel Hill, then joined the Broad Institute of MIT and Harvard where he developed cutting-edge mass spectrometry methods in Steven Carr's Proteomics Platform Lab.

Andrew is an NSF Graduate Research Fellowship Program (NSF-GRFP) fellow and Ph.D. candidate at Stanford University, co-advised by 2022 Nobel Laureate in Chemistry Dr. Carolyn Bertozzi and Dr. Or Gozani.

At 10x Science, Andrew co-leads a Stanford-rooted team with 18+ years of collective domain expertise and 47+ scientific publications, targeting the critical bottleneck between AI-driven drug discovery and clinical candidate preparation.

10x Science is backed by Y Combinator and seed funding, and is onboarding biopharma, biotech, and CRO customers with a platform that enables scientists to characterize proteins 10x faster than current solutions.